Cite
HARVARD Citation
Soria, J. et al. (n.d.). Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet oncology. 16 (8), pp. 897-907. [Online].